发明授权
- 专利标题: Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins
-
申请号: US10447308申请日: 2003-05-27
-
公开(公告)号: US07026328B2公开(公告)日: 2006-04-11
- 发明人: Andrei W. Konradi , Christopher M. Semko , Ying-zi Xu , Frank Stappenbeck , Brian P. Stupl , Jenifer L. Smith , Michael A. Pleiss , Eugene D. Thorsett
- 申请人: Andrei W. Konradi , Christopher M. Semko , Ying-zi Xu , Frank Stappenbeck , Brian P. Stupl , Jenifer L. Smith , Michael A. Pleiss , Eugene D. Thorsett
- 申请人地址: US CA South San Francisco US NJ Madison
- 专利权人: Elan Pharmaceuticals, Inc.,Wyeth
- 当前专利权人: Elan Pharmaceuticals, Inc.,Wyeth
- 当前专利权人地址: US CA South San Francisco US NJ Madison
- 代理机构: Foley & Lardner LLP
- 主分类号: C07D239/50
- IPC分类号: C07D239/50 ; A61K31/505
摘要:
Disclosed are compounds which bind α4 integrins, preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by α4 integrins, preferably VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.